Research Information System
33rd International Congress of Antimicrobial Chemotherapy (ICC), İstanbul, Turkey, 3 - 06 December 2024, vol.39, no.7, pp.14-15, (Summary Text)
In many pediatric wards, infections caused by GNB are increas- ingly resulting in significant morbidity and mortality. For the infec- tions with CR-GNB, a choice of treatment in children is prolonged infusions of carbapenem, particularly the meropenem. To assess the effectiveness of prolonged meropenem infusion (PMI) in chil- dren with carbapenem resistant (CR) Gram negative bacteria (GNB) infectionsThe present study included pediatric patients between 1 month and 18 years of age who were hospitalised and presented with bac- teremia with a positive blood culture with CR-GNB. We analysed the causative microorganism, susceptibility profile, the antimicro- bials used in combination with PMI. Outcome measures were neg- ative blood culture 14-day and 30-day mortality, and recurrence of infection in 14 days of completion of treatment. Between Jun 2022 and July 2024, a total of 19 (10 male, 9 fe- male) children with 26 infections were recorded. The most com- mon underlying disease was hemato-oncological disease, followed by chronic lung disease. Among the causative microorganisms, n = 16 (61%) {Klebsiella} spp, n = 7 (27%) {Pseudomonas} spp., n = 1 (3.8%) {Ochromobacter} spp, n = 1 (3.8%) {E. coli } were detected. Three infections recurred in the 14 days of completion of treat- ment. Seven (36.8%) patients died within 14 days of infection. Four of the patients who died had bone marrow transplant, one had chronic pulmonary disease, one with renal transplantation, and one had operated congenital heart effect. In pediatric infections with CR-GNB, PMI in combination with other GNB-active agents may be a reasonable choice. The mortality is closely related to the underlying disease and immune status.